Platelet Glycoprotein IIb/IIIa Integrin Blockade with Eptifibatide in Coronary Stent Intervention. The ESPRIT Trial: A Randomized Controlled Trial - ESPRIT Trial 6 Month Follow-up

Description:

Patient with coronary artery disease scheduled to undergo stent implantation were randomized to placebo or to eptifibatide. Eptifibatide administration included two 180 mcg/kg boluses10 min apart followed by an infusion of 2 mcg/kg/min for 18–24 hours. Bailout-blinded IIb/IIIa receptor therapy was allowed by providing a bailout kit containing eptifibatide for patients randomized to placebo and placebo for patients randomized to eptifibatide. Clinical end points evaluated included death or ...